Aurobindo Pharma announced its results for the second quarter of 2026–27 (July–September) on Wednesday, November 4. Both revenue and profit rose sharply.
The numbers
- Revenue: ₹10,263 crore, up 23.9%, the company's highest quarterly revenue.
- Net profit: ₹1,124 crore, against ₹848.13 crore a year earlier, up 32.5%.
- EBITDA: ₹2,156 crore, up 28.5%; margin up from 20.3% to 21%.
- Interim dividend: ₹7 per share.
By market
- US formulations: ₹4,555 crore, up 25%
- Europe formulations: ₹3,161 crore, up 27%
- Growth markets: ₹1,026 crore, up 16%; APIs: ₹1,162 crore, up 21%
The US and Europe together made up nearly three-quarters of revenue. The company received 12 final USFDA approvals in the quarter and held net cash of $189 million at the end of September. No share-price reaction was reported in the sources reviewed.
